Zhengxiang Han

Grit Biotechnology is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation tumor-infiltrating lymphocyte (TIL) therapies for advanced solid tumors. The company focuses on engineering TILs to overcome the immunosuppressive tumor microenvironment, utilizing technologies such as CRISPR-based gene editing and cytokine-armoring (e.g., membrane-bound IL-15) to enhance cell persistence and anti-tumor efficacy. Its lead programs, including GT101 and the engineered GT201, have demonstrated promising clinical activity in patients with heavily pretreated cancers such as non-small cell lung cancer and head and neck squamous cell carcinoma. Dr. Zhengxiang Han, a prominent oncologist at the Affiliated Hospital of Xuzhou Medical University, serves as a key clinical investigator for several of the company's primary therapeutic programs.